R&D CAMP4 on a new class of ASO in gene under expression CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
News CAMP4 raises $100m to take lead RNA drugs into clinic Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to
News Novartis sets sights on new oral MS drug after phase 3 wins Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
